Gapping up
In reaction to strong earnings/guidance: SIMO +7.3%, .
Other news: CYTX +16% (receives notice of intent to exercise first contract option from BARDA), BDSI +15% (Co and ENDP announce positive top-line results from the Phase III clinical trial of BEMA buprenorphine in opioid-experienced patients with chronic pain), PAL +10% (announces reduction of senior secured term loan interest rate and extension of credit facility), MNGA +8.4% (announced that the results of the recent Swine Manure Sterilization trials meet Rule 503.32 requirements making swine manure suitable for Class A treatment.), PMFG +4.9% ( awarded new SCR system orders for Asia valued at more than $10 mln), SPPI +4.5% (FDA grants accelerated approval of Beleodaq (belinostat) for injection), RSH +4.2% (still checking), NGD +3.3% (announces 24% increase in new afton C-zone gold measured and indicated mineral resources), SNTA +2% (cont strength), GPRO +1.7% (Cont strength), RLGY +1.7% (positive Barron's mention), CGEN +1.6% (discloses achievement of milestone in cancer immunotherapy collaboration with Bayer (BAYRY)), WTW +1.6% (positive Barron's mention), CASI +1.5% (receives U.S. Orphan Drug Designation for the use Of ENMD-2076 to treat hepatocellular carcinoma), CBI +1.4% (Awarded $60 mln Sphere Storage Contract By Petrofac ).
Analyst comments: KING +4.4% (upgraded to Overweight from Neutral at Piper Jaffray), MOBL +3.9% (initiated with a Buy at Goldman among others), SONS +3.8% (initiated with an Outperform at Pacific Crest), UTEK +3.5% (upgraded to at ), BXE +2.8% (positive comments from Northland), AMAT +2.7% (upgraded to Overweight from Neutral at JP Morgan), SEAS +1.7% (upgraded to Outperform from Mkt Perform at BMO Capital Mkts), CENX +1.5% (upgraded to Neutral from Sell at Goldman), SCCO +1.3% (upgraded to Buy from Neutral at BofA/Merrill), NAO +1.1% (initiated with a Outperform at Credit Suisse), VC +1.1% (resumed with a Overweight at JP Morgan), WSM +1% (upgraded to Buy from Neutral at BofA/Merrill)
In reaction to strong earnings/guidance: SIMO +7.3%, .
Other news: CYTX +16% (receives notice of intent to exercise first contract option from BARDA), BDSI +15% (Co and ENDP announce positive top-line results from the Phase III clinical trial of BEMA buprenorphine in opioid-experienced patients with chronic pain), PAL +10% (announces reduction of senior secured term loan interest rate and extension of credit facility), MNGA +8.4% (announced that the results of the recent Swine Manure Sterilization trials meet Rule 503.32 requirements making swine manure suitable for Class A treatment.), PMFG +4.9% ( awarded new SCR system orders for Asia valued at more than $10 mln), SPPI +4.5% (FDA grants accelerated approval of Beleodaq (belinostat) for injection), RSH +4.2% (still checking), NGD +3.3% (announces 24% increase in new afton C-zone gold measured and indicated mineral resources), SNTA +2% (cont strength), GPRO +1.7% (Cont strength), RLGY +1.7% (positive Barron's mention), CGEN +1.6% (discloses achievement of milestone in cancer immunotherapy collaboration with Bayer (BAYRY)), WTW +1.6% (positive Barron's mention), CASI +1.5% (receives U.S. Orphan Drug Designation for the use Of ENMD-2076 to treat hepatocellular carcinoma), CBI +1.4% (Awarded $60 mln Sphere Storage Contract By Petrofac ).
Analyst comments: KING +4.4% (upgraded to Overweight from Neutral at Piper Jaffray), MOBL +3.9% (initiated with a Buy at Goldman among others), SONS +3.8% (initiated with an Outperform at Pacific Crest), UTEK +3.5% (upgraded to at ), BXE +2.8% (positive comments from Northland), AMAT +2.7% (upgraded to Overweight from Neutral at JP Morgan), SEAS +1.7% (upgraded to Outperform from Mkt Perform at BMO Capital Mkts), CENX +1.5% (upgraded to Neutral from Sell at Goldman), SCCO +1.3% (upgraded to Buy from Neutral at BofA/Merrill), NAO +1.1% (initiated with a Outperform at Credit Suisse), VC +1.1% (resumed with a Overweight at JP Morgan), WSM +1% (upgraded to Buy from Neutral at BofA/Merrill)